IP Library Granted Patent US 8,404,849
Granted Patent B2
US 8,404,849 · App. 13/112,868 · Granted Mar 26, 2013

Processes for producing modulators of cystic fibrosis transmembrane conductance regulator

Inventors: Lifang Sun (La Mesa, CA); Khisal Ahmed Alvi (San Diego, CA); Caroline Joyce Decker (Encinitas, CA); Yongmin Li (San Diego, CA)
Assignee: Vertex Pharmaceuticals
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,404,849
App. No.
13/112,868
Granted
Mar 26, 2013
Kind
B2
Abstract

The present invention relates to the process for producing modulators of cystic fibrosis transmembrane conductance regulator (CFTR).

Claims (19)

1. A method of producing the compounds of Formula I:

or pharmaceutically acceptable salts thereof, wherein R 1 is —C F 3 , R 2 is —CF 3 , R 3 is H, and ring A is selected from

comprising

contacting the compound of Formula II with a CYP-102 enzyme, BM3-M11, to produce a mixture of compounds of Formula I, wherein the compound of Formula II has the structure

in which R 1 is —CF 3 , R 2 is —CF 3 , R 3 is H, and ring A is

2. The method of claim 1 , wherein the process is optionally conducted in the presence of an organic solvent.

3. The method of claim 2 , wherein the solvent is acetonitrile, methanol, acetone, dimethylsulfoxide, and dimethylformamide or mixtures thereof.

4. The method of claim 3 , wherein the process is conducted in the presence of methanol.

5. The method of claim 2 , wherein the organic solvent is present in an amount of less than about 30% (v/v).

6. The method of claim 5 , wherein the organic solvent is present in an amount of less than about 25% (v/v).

7. The method of claim 5 , wherein the organic solvent is present in an amount of less than or equal to about 20% (v/v).

8. The method of claim 2 , wherein the organic solvent is present in an amount of between about 5% to about 25% (v/v).

9. The method of claim 8 , wherein the organic solvent is present in an amount of between about 10% to about 20% (v/v).

10. The method of claim 1 , further comprising separating the mixture of compounds of Formula I.

11. The method of claim 10 , wherein the Exo and Endo isomers and each of their enantiomeric pairs of present in the mixture of compounds of Formula I are separated by chiral LC-MS/MS.

12. The method of claim 11 , wherein ring A of the separated isomer of Formula I is

13. The method of claim 11 , wherein ring A of the separated isomer of Formula I is

14. The method of claim 11 , wherein ring A of the separated isomer of Formula I is

15. The method of claim 11 , wherein ring A of the separated isomer of Formula I is

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Oct 14, 2016
From: MACQUARIE US TRADING LLC
To: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
Reel/Frame 040357/0001 →
ASSIGNEE CHANGE OF ADDRESS Recorded Feb 17, 2016
From: VERTEX PHARMACEUTICALS INCORPORATED
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 037845/0106 →
SECURITY INTEREST Recorded Jul 10, 2014
From: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 033292/0311 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2011
From: SUN, LIFANG; ALVI, KHISAL AHMED; DECKER, CAROLINE JOYCE; LI, YONGMIN
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 026484/0180 →
Continuity (3)
Provisional Application 61346781 · May 20, 2010
Provisional Application 61379614 · Sep 2, 2010
Related Publication 20110288121A1 · Nov 24, 2011